<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">699336</article-id><article-id pub-id-type="doi">10.35693/SIM699336</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Surgery</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Хирургия</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Use of botulinum toxin type A in the preoperative preparation of patients with ventral hernias: effect on the postoperative period</article-title><trans-title-group xml:lang="ru"><trans-title>Применение ботулинического токсина типа А в предоперационной подготовке пациентов с вентральными грыжами: влияние на течение послеоперационного периода</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1177-6424</contrib-id><name-alternatives><name xml:lang="en"><surname>Akhmadeeva</surname><given-names>Leila R.</given-names></name><name xml:lang="ru"><surname>Ахмадеева</surname><given-names>Лейла Ринатовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor of the Department of Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры неврологии</p></bio><email>leila_ufa@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4832-1682</contrib-id><name-alternatives><name xml:lang="en"><surname>Galimov</surname><given-names>Oleg V.</given-names></name><name xml:lang="ru"><surname>Галимов</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Head of the Department of Surgical Diseases, Medical Faculty</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующий кафедрой хирургических болезней лечебного факультета</p></bio><email>galimovov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4910-5383</contrib-id><name-alternatives><name xml:lang="en"><surname>Gizatullin</surname><given-names>Rinat R.</given-names></name><name xml:lang="ru"><surname>Гизатуллин</surname><given-names>Р. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>assistant of the Department of Neurology; Acting Head of the Neurology Department of the BSMU Clinic</p></bio><bio xml:lang="ru"><p>ассистент кафедры неврологии, исполняющий обязанности заведующего отделением неврологии Клиники БГМУ</p></bio><email>gizatullinrr@neuroufa.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-3391-4735</contrib-id><name-alternatives><name xml:lang="en"><surname>Allayarov</surname><given-names>Nail D.</given-names></name><name xml:lang="ru"><surname>Аллаяров</surname><given-names>Н. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>assistant of the Department of Surgical Diseases; Head of the Admission Department, Surgeon of the BSMU Clinic</p></bio><bio xml:lang="ru"><p>ассистент кафедры хирургических болезней лечебного факультета; заведующий приемным отделением, врач-хирург Клиники БГМУ</p></bio><email>allayarovnd@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4160-2820</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakeev</surname><given-names>Marat R.</given-names></name><name xml:lang="ru"><surname>Бакеев</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>resident of the Department of Surgical Diseases</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры хирургических болезней лечебного факультета</p></bio><email>m.r.bakeev@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-3685-422X</contrib-id><name-alternatives><name xml:lang="en"><surname>Valitova</surname><given-names>Elvira V.</given-names></name><name xml:lang="ru"><surname>Валитова</surname><given-names>Э. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>resident of the Department of Neurology</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры неврологии</p></bio><email>elviravltva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Bashkir State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-01-26" publication-format="electronic"><day>26</day><month>01</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-02-19" publication-format="electronic"><day>19</day><month>02</month><year>2026</year></pub-date><volume>11</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>63</fpage><lpage>68</lpage><history><date date-type="received" iso-8601-date="2025-12-26"><day>26</day><month>12</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-01-22"><day>22</day><month>01</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Akhmadeeva L.R., Galimov O.V., Gizatullin R.R., Allayarov N.D., Bakeev M.R., Valitova E.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Ахмадеева Л.Р., Галимов О.В., Гизатуллин Р.Р., Аллаяров Н.Д., Бакеев М.Р., Валитова Э.В.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Akhmadeeva L.R., Galimov O.V., Gizatullin R.R., Allayarov N.D., Bakeev M.R., Valitova E.V.</copyright-holder><copyright-holder xml:lang="ru">Ахмадеева Л.Р., Галимов О.В., Гизатуллин Р.Р., Аллаяров Н.Д., Бакеев М.Р., Валитова Э.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/699336">https://innoscience.ru/2500-1388/article/view/699336</self-uri><abstract xml:lang="en"><p><bold>Aim:</bold> to evaluate the effect of preoperative botulinum toxin type A (BoNT-A) administration on the early postoperative period in patients with large incisional ventral hernias (IVH) compared with a control group.</p> <p><bold>Material and methods.</bold> A retrospective analysis of 19 patients with IVH class W3 (EHS classification) was performed. The main group (n=9) included patients who received preoperative BoNT-A injections (Dysport 900-1000 U or Xeomin 200 U) into the lateral abdominal muscles under US guidance followed by TAR repair. The control group (n=10) included patients operated without BoNT-A preparation (methods: TAR, Rives-Stoppa, TAR+bridge). The operative time, intensity of pain syndrome according to VAS on days 1, 3 and 5, the duration of opioid analgesic use, the frequency and structure of complications, and the length of hospital stay were evaluated.</p> <p><bold>Results.</bold> In the BoNT-A group, pain intensity was significantly lower on day 1 (VAS median 18.0 [11.5; 26.0] mm vs. 43.5 [40.0; 52.8] mm in control, p&lt;0.001), day 3 (11.0 [8.5; 13.0] mm vs. 41.5 [38.0; 42.8] mm, p&lt;0.001) and day 5 (2.0 [1.0; 3.5] mm vs. 31.5 [29.0; 33.0] mm, p&lt;0.001). The overall complication rate in the BoNT-A group was 11.1% (surgical site hematoma in 1 patient) vs. 70.0% in the control group (p=0.027), with no infectious complications recorded in the BoNT-A group (0% vs. 40.0% in control, p=0.087). The median length of hospital stay in the BoNT-A group was 8.0 [7.0; 8.0] days vs. 9.0 [8.0; 15.8] days in the control group (p=0.095).</p> <p><bold>Conclusion. </bold>Preoperative botulinum therapy is a safe and effective method that significantly reduces the intensity of postoperative pain and the frequency of complications in patients with large ventral hernias.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель:</bold> оценить влияние предоперационного введения ботулинического токсина типа А (БТА) на течение раннего послеоперационного периода у пациентов с большими послеоперационными вентральными грыжами (ПОВГ) в сравнении с контрольной группой.</p> <p><bold>Материал и методы. </bold>Проведен ретроспективный анализ 19 пациентов с ПОВГ класса W3 по классификации EHS. Основную группу (n=9) составили пациенты, получившие предоперационные инъекции БТА (Диспорт 900-1000 ЕД или Ксеомин 200 ЕД) в боковые мышцы живота под УЗ-контролем с последующей герниопластикой TAR. Контрольную группу (n=10) составили пациенты, оперированные без подготовки БТА (методы: TAR, Rives – Stoppa, TAR+bridge). Оценивались время операции, интенсивность болевого синдрома по ВАШ (визуально-аналоговая шкала) на первые, третьи и пятые сутки, продолжительность применения опиоидных анальгетиков, частота и структура осложнений, длительность госпитализации.</p> <p><bold>Результаты. </bold>В группе БТА интенсивность боли была достоверно ниже на первые сутки (медиана ВАШ 18,0 [11,5; 26,0] мм против 43,5 [40,0; 52,8] мм в контроле, p &lt;0,001), на третьи сутки (11,0 [8,5; 13,0] мм против 41,5 [38,0; 42,8] мм, p &lt;0,001) и на пятые сутки (2,0 [1,0; 3,5] мм против 31,5 [29,0; 33,0] мм, p &lt;0,001). Общая частота осложнений в группе БТА составила 11,1% (гематома послеоперационной раны у одного пациента) против 70,0% в контроле (p=0,027), при этом инфекционные осложнения в группе БТА зафиксированы не были (0% против 40,0% в контроле, p=0,087). Медиана длительности госпитализации в группе БТА составила 8,0 [7,0; 8,0] дня против 9,0 [8,0; 15,8] дня в контроле (p=0,095).</p> <p><bold>Заключение. </bold>Предоперационная ботулинотерапия является безопасным и эффективным методом, достоверно снижающим интенсивность послеоперационной боли и частоту осложнений у пациентов с большими вентральными грыжами.</p></trans-abstract><kwd-group xml:lang="en"><kwd>botulinum toxin type A</kwd><kwd>ventral hernia</kwd><kwd>preoperative preparation</kwd><kwd>postoperative period</kwd><kwd>chemical component separation</kwd><kwd>pain</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ботулинический токсин типа А</kwd><kwd>вентральная грыжа</kwd><kwd>предоперационная подготовка</kwd><kwd>послеоперационный период</kwd><kwd>химическая компонентная сепарация</kwd><kwd>боль</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Saiding Q, Chen Y, Wang J, et al. Abdominal wall hernia repair: from prosthetic meshes to smart materials. Mater Today Bio. 2023;21:100691. DOI: 10.1016/j.mtbio.2023.100691</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ortega-Deballon P, Renard Y, de Launay J, et al. Incidence, risk factors, and burden of incisional hernia repair after abdominal surgery in France: a nationwide study. Hernia. 2023;27(4):861-871. DOI: 10.1007/s10029-023-02825-9</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Muysoms FE, Miserez M, Berrevoet F, et al. Classification of primary and incisional abdominal wall hernias. Hernia. 2009;13(4):407-414. DOI: 10.1007/s10029-009-0518-x</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Weissler JM, Lanni MA, Tecce MG, et al. Chemical component separation: a systematic review and meta-analysis of botulinum toxin for management of ventral hernia. J Plast Surg Hand Surg. 2017;51(5):366-374. DOI: 10.1080/2000656X.2017.1285783</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Pauli EM, Wang J, Petro CC, et al. Posterior component separation with transversus abdominis release successfully addresses recurrent ventral hernias following anterior component separation. Hernia. 2015;19(2):285-91. DOI: 10.1007/s10029-014-1331-8</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Love MW, Warren JA, Davis S, et al. Computed tomography imaging in ventral hernia repair: can we predict the need for myofascial release? Hernia. 2021;25(2):471-477. DOI: 10.1007/s10029-020-02181-y</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ibarra-Hurtado TR, Nuño-Guzmán CM, Echeagaray-Herrera JE, Robles-Vélez E, de Jesús González-Jaime J. Use of botulinum toxin type a before abdominal wall hernia reconstruction. World J Surg. 2009;33(12):2553-2556. DOI: 10.1007/s00268-009-0203-3</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Farooque F, Jacombs AS, Roussos E, et al. Preoperative abdominal muscle elongation with botulinum toxin A for complex incisional ventral hernia repair. ANZ J Surg. 2016;86(1-2):79-83. DOI: 10.1111/ans.13258</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Rodriguez-Acevedo O, Elstner KE, Jacombs ASW, et al. Preoperative Botulinum toxin A enabling defect closure and laparoscopic repair of complex ventral hernia. Surg Endosc. 2018;32(2):831-839. DOI: 10.1007/s00464-017-5750-3</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nielsen MØ, Bjerg J, Dorfelt A, et al. Short-term safety of preoperative administration of botulinum toxin A for the treatment of large ventral hernia with loss of domain. Hernia. 2020;24(2):295-299. DOI: 10.1007/s10029-019-01957-1</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Elstner KE, Jacombs ASW, Read JW, et al. Laparoscopic repair of complex ventral hernia facilitated by pre-operative chemical component relaxation using Botulinum Toxin A. Hernia. 2016;20(2):209-219. DOI: 10.1007/s10029-016-1478-6</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: The “Statistical Analyses and Methods in the Published Literature” or the SAMPL Guidelines. Int J Nurs Stud. 2015;52(1):5-9. DOI: 10.1016/j.ijnurstu.2014.09.006</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zendejas B, Khasawneh MA, Srvantstyan B, et al. Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs. World J Surg. 2013;37(12):2830-2837. DOI: 10.1007/s00268-013-2211-6</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Akhmadeeva LR, Rakhimova ASh, Allayarov ND, et al. Botulinum toxin type A in the surgical treatment of anterior abdominal wall muscle dystonia in ventral hernias: a systematic review and our experience. Effektivnaya Farmakoterapiya. 2025;21(21):30-39. [Ахмадеева Л.Р., Рахимова А.Ш., Аллаяров Н.Д., и др. Применение ботулинического токсина типа А в хирургическом лечении дистонии мышц передней брюшной стенки при вентральных грыжах: систематический обзор и собственный опыт. Эффективная фармакотерапия. 2025;21(21):30-39]. DOI: https://doi.org/10.33978/2307-3586-2025-21-21-30-39</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Timmer AS, Claessen JJM, Atema JJ, et al. A systematic review and meta-analysis of technical aspects and clinical outcomes of botulinum toxin prior to abdominal wall reconstruction. Hernia. 2021;25(6):1413-1425. DOI: 10.1007/s10029-021-02499-1</mixed-citation></ref></ref-list></back></article>
